Imunon Inc. Grants Retiring Chief Scientific Officer Severance and Consulting Retainer

Reuters
Feb 05
Imunon Inc. Grants Retiring Chief Scientific Officer Severance and Consulting Retainer

Imunon Inc. has announced that Executive Vice President and Chief Scientific Officer Khursheed Anwer will retire effective February 20, 2026. Following his retirement, Dr. Anwer will transition to a consulting role with the company through December 31, 2026, receiving a monthly retainer of $10,000 during this period. Additionally, under the terms of a retirement and consulting agreement, he will be entitled to receive any accrued but unpaid salary and unreimbursed business expenses within 30 days of his retirement, continued payment of his base salary as severance for twelve months, and company-paid COBRA health coverage for the same duration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Imunon Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-005203), on February 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10